Regeneron Earnings Beat. Forecasts as Sales of Updated Eye Drug Raise Hopes
Regeneron hopes to limit the damage from the expiration of the patent on its key drug Eylea with a new version of the treatment.
Source: marketwatch.com
Fr San News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fr San. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fr San Today - Breaking & Trending Today
Sanofi Expected to Report Higher Sales on Dupixent Growth -- Earnings Preview
By Adria Calatayud Sanofi is scheduled to report results for the fourth quarter on Thursday. Here is what you need to know. SALES FORECAST: Analysts expect...
Source: marketwatch.com
Regeneron, Sanofi Get FDA OK for Esophagus Inflammation Treatment in Younger Children
By Ben Glickman Regeneron Pharmaceuticals and Sanofi's Dupilumab received approval from the U.S. Food and Drug Administration for a treatment of an esophagus...
Source: marketwatch.com
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.
Source: marketwatch.com
How Lowering The Price of a Common Asthma Drug Made it Harder to Get
To avoid Medicaid penalties, Glaxo and other drugmakers lowered prices. For popular asthma drug Flovent HFA, the tactic to replace it with a generic backfired.
Source: wsj.com